Algocell. AI Ltd

Based in Israel, Algocell. AI Ltd specializes in artificial intelligence-driven bioprocess optimization, providing advanced platform solutions that greatly enhance efficiency in biopharmaceutical manufacturing. Algocell, founded in 2023 in Rehovot, Israel, by Co- founders CTO Eyal Betzalel, CEO Omri Schanin and Chairman David Almagor PhD, focuses on AI-driven bioprocess optimization. The company has not undergone any major strategic pivots.

It is recognized for its two successful deals, the most recent of which occurred on July 2, 2025. The company operates independently and was not formed through any mergers or carve-outs. Information about the founder is currently not available. Algocell specializes in AI-powered bioprocess optimization through its advanced platform, integrating hybrid models and digital twins.

Their solutions enable clients to efficiently construct bioprocess Digital Twins, significantly reducing the time and resources needed for trial and error in bioprocess development and scale-up. The platform optimizes cell productivity while utilizing hybrid models for real-time insights during production. Algocell's diverse clientele includes biopharmaceutical companies and contract manufacturing organizations (CMOs) across regions such as North America, Europe, and parts of Asia, helping them improve their manufacturing processes and mitigate operational failures. Algocell generates revenue through a subscription-based model, granting clients access to its bioprocess optimization platform.

The company employs a tiered pricing structure to meet various client needs, which includes basic platform access and premium support options. Revenue transactions are primarily B2B, with biopharmaceutical companies and CMOs subscribing to utilize Algocell’s technology for enhancing their bioprocess workflows. Key offerings within this model include the calibration of Algocell's hybrid models, aiding the development of tailored optimization protocols that foster customer satisfaction and strengthen long-term partnerships. In July 2025, Algocell secured an undisclosed amount of grant funding from the Israel Innovation Authority and individual investors, as part of a total USD 2.

8 mn pre-seed and grant funding initiative. The company plans to utilize this funding to expand its team and enhance its platform’s predictive features. Looking ahead, Algocell aims to introduce new products to bolster its capabilities and is targeting expansion into additional markets, though specific regions for growth have not been disclosed.